Kenvue (NYSE:KVUE), traded as KVUE on the New York Stock Exchange, is a global consumer health company that began operations as an independent public entity in May 2023 following its spin-off from Johnson & Johnson’s consumer health division. The move established Kenvue as a standalone organization focused on delivering trusted over-the-counter and personal care products. Drawing on a legacy of more than a century of consumer-centric innovation, Kenvue aims to sharpen its focus on brand building, product development and market responsiveness.
The company’s portfolio spans multiple core categories, including pain relief, skin health, respiratory care, oral care and wound management. Renowned brand names under the Kenvue umbrella include Tylenol and Motrin for pain management, Neutrogena and Aveeno for dermatological care, Listerine for oral hygiene, and Band-Aid for wound treatment. Kenvue invests in research and development to enhance product formulations, packaging sustainability and consumer convenience, seeking to address everyday health and wellness needs.
Kenvue serves approximately 100 markets across North America, Europe, Latin America, Asia-Pacific and the Middle East/Africa. The company operates a network of manufacturing facilities and regional offices designed to bolster supply-chain resilience and align product offerings with local market preferences. Through strategic partnerships with pharmacies, retail chains and digital channels, Kenvue maintains broad product availability and engages consumers across multiple distribution platforms.
Led by Chief Executive Officer Thibaut Mongon, Kenvue is guided by a board of directors and executive team with extensive experience in consumer healthcare and global supply-chain management. The leadership group emphasizes sustainable growth, operational excellence and investments in science-based innovation to strengthen the company’s position in the competitive consumer health landscape.
